Rhythm Pharmaceuticals reported topline results from EMANATE, a global, randomized, double-blind, placebo-controlled Phase 3 trial of setmelanotide in rare, genetically driven obesity due to melanocortin-4 receptor (MC4R) pathway variants. All four independent substudies missed the primary endpoint of placebo-adjusted percent change in BMI at week 52 in the modified intent-to-treat analysis with prespecified multiple imputation: POMC/PCSK1 heterozygous variants (n=78, –4.3%, p=0.15), LEPR heterozygous variants (n=23, –3.6%, p=0.94), SRC1/NCOA1 (n=73, –4.0%, p=0.12), and SH2B1 (n=121, –1.7%, p=0.43). Post hoc analyses using last observation carried forward showed statistically significant reductions in BMI for POMC/PCSK1 (–5.5%, p=0.0010) and SRC1 (–6.2%, p<0.0001), with larger effects in genetically confirmed completers at week 52 (POMC/PCSK1 –9.7%, p=0.0002; SRC1 –8.0%, p=0.0158). Safety was consistent with prior experience. Rhythm plans further analyses and is evaluating next-generation MC4R agonists, bivamelagon and RM-718. For a company already marketing setmelanotide for BBS and biallelic POMC/PCSK1/LEPR deficiency, EMANATE was the vehicle to broaden into heterozygous and additional MC4R-pathway genotypes. The miss narrows near-term expansion prospects and surfaces a strategic question: can biology-driven signals rescued in post hoc cuts be converted into prospectively defined, regulator-ready populations, or does Rhythm need a clean slate with next-generation agents and redesigned enrichment strategies? The implications are immediate across stakeholders. Patients with heterozygous variants and SRC1 or SH2B1 alterations still lack an approved, pathway-targeted option, extending dependence on nonspecific therapies and lifestyle measures. For payers navigating surging obesity budgets, the absence of statistically robust primary endpoint success weakens the case for broad coverage beyond existing labels, especially as placebo-adjusted BMI deltas in intent-to-treat groups were modest. Medical Affairs teams now face a heavier lift: precision selection hinges on distinguishing true loss-of-function from benign or uncertain variants, requiring tighter partnerships with genetic testing laboratories, standardized variant curation, and education on phenotype-genotype concordance. Off-label use is unlikely to gain traction without clear reimbursement pathways, making real-world evidence programs insufficient substitutes for prospective, pre-specified efficacy in the right subgroups. Commercially, the setback concentrates Rhythm’s growth back on BBS and biallelic indications while incretin-based therapies continue to command attention and budgets. Although setmelanotide addresses a mechanistically distinct, ultra-rare segment, payer scrutiny will sharpen around comparative value and absolute benefit size. Competitors in the obesity arena are advancing combination incretin and amylin approaches with strong weight loss signals; a niche precision asset must demonstrate unequivocal benefit in a genetically defined population to avoid being crowded out in formulary negotiations and care pathways increasingly standardized around GLP-1-centric regimens. Industry-wide, EMANATE underscores the maturing reality of precision obesity: genetics alone is not enough. Functional validation, stringent variant adjudication, and prospectively enriched designs are becoming prerequisites, mirroring oncology’s evolution from broad biomarker labels to companion diagnostics with assay-level rigor. Adaptive and basket-trial methodologies, centralized genetic curation, and earlier alignment with regulators on analytic methods for missing data may determine the success of future programs. Rhythm’s pivot to next-generation MC4R agonists suggests a bid for greater potency, pharmacokinetic elegance, or tolerability to amplify effect sizes in precisely curated subgroups. The next move will define the trajectory: a prospectively powered, enrichment-driven trial in genetically confirmed loss-of-function heterozygous POMC/PCSK1 and SRC1, with pre-specified analyses and payer-relevant endpoints, or a reset around bivamelagon and RM-718 using adaptive designs to lock in responders early. The strategic test is whether Rhythm can translate a biological signal into a registrationally credible label and a reimbursable value story before obesity care hardens around entrenched incretin-first algorithms.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
